Ocular Therapeutix jumps as TD Cowen upgrades to Buy and hikes PT

da-kuk Shares of Ocular Therapeutix ( NASDAQ: OCUL ) gained 12% on Thursday as brokerage TD Cowen upgraded the company to Buy from Hold and raised its price target to $11 from $7. "The SOL-1 enrollment is going great due to the experienced team and strong KOL support," said analysts at TD Cowen. The brokerage added SOL-R (redosing) is an added perk that should enable real-world use and encourage further enrollment.

Axpaxli also appears active in NPDR, which encompasses 6.3M patients, and the ex-wAMD pipeline receives little credit, with TD Cowen seeing a $1 billion potential peak of Axpaxli in wAMD. Since the start of the year, Ocular Therapeutix shares have gained about 38%, outpacing the broader S&P 500 index.

Seeking Alpha's Quant has rated the stock as a Hold, while sell-side analysts recommended the company as a Buy. More on Ocular Therapeutix Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results Ocular Therapeutix jumps after investor day updates Ocular Therapeutix GAAP EPS of -$0.49 misses by $0.

29, revenue of $14.77M misses by $0.59M Seeking Alpha’s Quant Rating on Ocular Therapeutix.